OncoSec Medical Inc (ONCS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

24 N. MAIN STREET PENNINGTON, NJ 08534

OncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate - TAVO™ (tavokinogene telseplasmid) - enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions.

Data as of 2021-07-19 09:04:40 -0400
Market Cap94.436 Million Shares Outstanding39.185 Million Avg 30-day Volume5.112 Million
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.05 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.81245 52-week High/Low8.16 / 2.38 Next Earnings Date2021-10-27 Price to Cash FLow (P/CF) -9.7588
Data provided by IEX Cloud
View SEC Filings from ONCS instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 36 33 9.09% 16 (0.94%) 15 (0.87%) 6.67%
13F shares: 7.591 Million 4.255 Million 78.41% 6.391 Million 3.498 Million 82.7%
% Ownership 20.4273 15.1997 34.39% 17.1999 12.498 37.62%
New Positions: 10 9 11.11% 4 5 -20.0%
Increased Positions 17 14 21.43% 10 8 25.0%
Closed Positions 6 3 100.0% 2
Reduced Positions 4 7 -42.86% 2 2 0.0%
Total Calls 125
Total Puts
PUT/CALL Ratio 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ONCS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ONCS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

13.6 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DEMESA JAMES M

  • Director
25,000 2021-06-28 2

WARD ROBERT

  • Director
25,000 2021-06-28 2

KIM JOON

  • Director
25,000 2021-06-28 1

DALESANDRO MARGARET

  • Director
37,500 2021-06-28 2

DELAVERSANO ROBERT J VICE PRESIDENT, FINANCE

  • Officer
35,000 2021-06-28 4

ZHOU CHAO

  • Director
  • 10% Owner
25,000 2021-06-28 1

ZHAO YUHANG

  • Director
25,000 2021-06-28 1

SMITH KEVIN RAYMOND MERRILL

  • Director
25,000 2021-06-28 1

LYERLY HERBERT KIM

  • Director
25,000 2021-06-28 2

LEUTHNER BRIAN A INTERIM CEO

  • Officer
211,387 2021-06-28 3

O'CONNOR DANIEL J. CEO AND PRESIDENT

  • Officer
  • Director
96,097 2021-04-30 5

CHINA GRAND PHARMACEUTICAL & HEALTHCARE HOLDINGS LTD

GRAND DECADE DEVELOPMENTS LTD

SIRTEX MEDICAL US HOLDINGS, INC.

  • 10% Owner
  • SEE REMARKSSEE REMARKS
20,157,643 2021-04-16 1

ALPHA HOLDINGS, INC.

  • Director
1,718,251 2021-02-18 5

FOERTER KELLIE MALLOY CHIEF OPERATING OFFICER

  • Officer
0 2020-08-24 3

DHILLON AVTAR S

  • Director
No longer subject to file 2020-04-17 0

CHINA GRAND PHARMACEUTICAL & HEALTHCARE HOLDINGS LTD

SIRTEX MEDICAL US HOLDINGS, INC.

  • 10% Owner
  • SEE REMARKSSEE REMARKS
12,000,000 2020-02-07 2

BONSTEIN SARA CFO/COO

  • Officer
41,389 2020-01-16 0

DHILLON PUNIT

  • Director
0 2019-01-02 0

MAYES, GREGORY T.

  • Director
0 2019-01-02 0

SLANSKY RICHARD B CHIEF FINANCIAL OFFICER

  • Officer
270,016 2018-06-15 0

JENKINS ANNALISA

  • Director
0 2017-09-05 0

MOHAN-PETERSON SHEELA CHIEF LEGAL&COMPLIANCE OFFICER

  • Officer
9,520 2017-07-31 0

MAIDA ANTHONY E III

  • Director
0 2017-03-29 0

GARGOSKY SHARRON E CHIEF CLINICAL & REG. OFFICER

  • Officer
0 2017-03-29 0

PIERCE ROBERT HAMILTON CHIEF SCIENTIFIC OFFICER

  • Officer
0 2016-03-04 0

LE MAI HOPE CHIEF MEDICAL OFFICER

  • Officer
0 2015-08-20 0

VALLEJO VERONICA CHIEF FINANCIAL OFFICER

  • Officer
0 2015-03-03 0

CROSS MICHAEL CHIEF OPERATING OFFICER

  • Officer
1,214,000 2011-03-10 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

DALESANDRO MARGARET - Director

2021-06-29 19:36:23 -0400 2021-06-28 A 37,500 a 37,500 direct

DEMESA JAMES M - Director

2021-06-29 19:46:52 -0400 2021-06-28 A 25,000 a 25,000 direct

SMITH KEVIN RAYMOND MERRILL - Director

2021-06-29 19:41:56 -0400 2021-06-28 A 25,000 a 25,000 direct

LEUTHNER BRIAN A - Officer INTERIM CEO

2021-06-29 19:42:09 -0400 2021-06-28 A 192,000 a 192,000 direct 2.847 13.5231 20.9964 5 -0.7117 4

LYERLY HERBERT KIM - Director

2021-06-29 19:39:05 -0400 2021-06-28 A 25,000 a 25,000 direct

DELAVERSANO ROBERT J - Officer VICE PRESIDENT, FINANCE

2021-06-29 19:43:42 -0400 2021-06-28 A 35,000 a 35,000 direct

LEUTHNER BRIAN A - Officer INTERIM CEO

2021-06-29 19:42:09 -0400 2021-06-28 A 33,000 a 33,000 direct

WARD ROBERT - Director

2021-06-29 19:37:26 -0400 2021-06-28 A 25,000 a 25,000 direct

KIM JOON - Director

2021-06-29 19:35:43 -0400 2021-06-28 A 25,000 a 25,000 direct

ZHOU CHAO - Director - > 10% Owner

2021-06-29 19:40:25 -0400 2021-06-28 A 25,000 a 25,000 direct

LEUTHNER BRIAN A - Officer INTERIM CEO

2021-06-29 19:42:09 -0400 2021-06-28 S 13,613 $3.16 d 178,387 direct 2.847 13.5231 20.9964 5 -0.7117 4

ZHAO YUHANG - Director

2021-06-29 19:38:56 -0400 2021-06-28 A 25,000 a 25,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ONCOSEC MEDICAL INC ONCS 2021-07-23 22:15:03 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 21:45:03 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 21:15:03 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 20:45:03 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 20:15:05 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 19:45:03 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 19:15:03 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 18:45:03 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 18:15:03 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 17:45:03 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 17:15:02 UTC -6.336 6.416 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 16:45:02 UTC -5.9442 6.0242 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 16:15:03 UTC -5.9442 6.0242 450000
ONCOSEC MEDICAL INC ONCS 2021-07-23 15:45:02 UTC -5.9442 6.0242 400000
ONCOSEC MEDICAL INC ONCS 2021-07-23 15:15:03 UTC -5.9442 6.0242 400000
ONCOSEC MEDICAL INC ONCS 2021-07-23 14:45:03 UTC -5.9442 6.0242 400000
ONCOSEC MEDICAL INC ONCS 2021-07-23 14:15:03 UTC -5.9442 6.0242 400000
ONCOSEC MEDICAL INC ONCS 2021-07-23 13:45:03 UTC -5.9442 6.0242 400000
ONCOSEC MEDICAL INC ONCS 2021-07-23 13:15:03 UTC -5.9442 6.0242 400000
ONCOSEC MEDICAL INC ONCS 2021-07-23 12:45:03 UTC -5.9442 6.0242 400000

Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin

Short Position History (International Only)

Holder Net Short Position Position Date Origin
Squarepoint Ops LLC OncoSec Medical Inc 0.64% 2019-05-31 UK
Squarepoint Ops LLC OncoSec Medical Inc 0.54% 2019-05-30 UK
Squarepoint Ops LLC OncoSec Medical Inc 1.98% 2019-08-15 UK

Elevate your investments